Gyeonggi, South Korea

Chan Hee Park

This inventor holds 1 USPTO granted patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chan Hee Park. Retrieved from https://idiyas.com/inventor/chan-hee-park-gddwycgs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Chan Hee Park

Introduction

Chan Hee Park is a notable inventor based in Kyunggi-do, South Korea. She has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds.

Latest Patents

One of her key patents is related to substituted phenethylamine derivatives. This patent focuses on substituted phenethylamine compounds of Formula (1) that function as motilin receptor antagonists. Chan Hee Park holds 1 patent in this area, showcasing her innovative approach to drug development.

Career Highlights

Chan Hee Park is currently employed at Chugai Seiyaku Kabushiki Kaisha, a prominent pharmaceutical company. Her work there emphasizes her commitment to advancing medical science through innovative research.

Collaborations

Throughout her career, Chan Hee Park has collaborated with esteemed colleagues such as Hiroharu Matsuoka and Tsutomu Sato. These partnerships have further enriched her research and development efforts.

Conclusion

Chan Hee Park's contributions to the field of pharmaceuticals highlight her innovative spirit and dedication to improving healthcare. Her work continues to inspire future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…